ロード中...
B-cell–targeted therapies in relapsing forms of MS
In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical tria...
保存先:
| 出版年: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5656409/ https://ncbi.nlm.nih.gov/pubmed/29082296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000405 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|